Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH

Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fatty liver disease MASH. It’s Madrigal’s fourth business development deal of the past year and the company’s second one involving siRNA therapies. The post Madrigal Pharma Adds Another Genetic Medicine to Its Drug…

Read More

CRUSHing Lab Fraud: Three Myths that Derail Real Reform

Leeza Osipenko Ekaterina Cleary Julie Egginton By JULIE EGGINGTON, EKATERINA CLEARY & LEEZA OSIPENKO When CMS issued its Request for Information under the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) initiative in February, it zeroed in on a long-festering problem: fraud, waste, and abuse in laboratory testing, especially in genetic and molecular diagnostics. The laboratory…

Read More